Latest Videos |view all videos
Bladder cancer treatment options
R. Jeffrey Karnes, M.D., consultant and associate professor, Mayo Clinic, discusses treatment options for bladder cancer. The ailment can be subdivided into subcategories, and the treatments dramatically differ. Invasive treatments can ...
Combined Therapy Benefits Cigarette Smokers Trying to Quit Compared to Monotherapy
Jon Ebbert, M.D., of the Mayo Clinic Nicotine Dependence Center, on a study combining the smoking cessation medications varenicline and bupropion, compared with varenicline alone, that resulted in higher smoking abstinence rates.
Expert comments on Surgeon General report about smoking
Richard D. Hurt, M.D., director of Mayo Clinic's Nicotine Dependence Center, comments on a new report by the Surgeon General released Jan. 2014, The Health Consequences of Smoking — 50 Years of Progress, which highlights a half-century ...
Mayo Clinic scientists propose a breast cancer drug for bladder cancer patients
Amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC), has shown that the presence of HER2 amplification is associated with particularly aggressive tumors.
Mayo Clinic researchers find 2 oncogenes join to drive lung squamous cell carcinoma
Alan P. Fields, Ph.D., and Dr. Monica Flynn Jacoby, professor of cancer studies at Mayo Clinic's campus in Florida, talk about the publication of his team's latest discovery.
Judy C. Boughey, M.D., and Matthew P. Goetz, M.D., present Breast Cancer Genome-Guided Therapy Study: Next-Generation Sequencing for the Management of Women With High-Risk Breast Cancer.
Canadian study: Screening mammograms do not cut breast cancer deaths
A study published today in the journal BMJ says annual screening mammograms in women ages 40 to 59 do not reduce deaths from breast cancer any better than a physical examination or usual care.
Grand Rounds: Targeting Polarity Pathways for Cancer Treatment
Panagiotis Z. Anastasiadis, Ph.D., presents Targeting Polarity Pathways for Cancer Treatment.
Lymphoma patients event-free two years after diagnosis have a normal life expectancy
Newly diagnosed patients with diffuse large B cell lymphoma (DLBCL) who do not experience any cancer-related outcome events for two years after diagnosis have essentially the same life expectancy as they did prior to diagnosis, a Mayo ...
Precursor of multiple myeloma more common in blacks than whites, Mayo study finds
Blacks may be twice as likely as whites to develop multiple myeloma because they are also more likely to have a precursor condition known as monoclonal gammopathy of undetermined significance.
Faster tumor analysis software speeds cancer discoveries
With the glut of data generated through next-generation sequencing, interpretation has become the new bottleneck in scientific discovery and clinical application.
Minority disparities evident in prostate cancer survival rate, Mayo Clinic study shows
A Mayo Clinic study reviewed data on more than 290,000 men with prostate cancer from the past 20 years and found that African-American men are at increased risk of poorer survival rate following prostate cancer treatment compared with other minority groups.